US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Medicus Pharma Ltd.

0.1614

-0.0090-5.28%

Pre-market: 0.1594-0.0020-1.24%07:21 EDT

Volume:18.16M

Turnover:3.14M

Market Cap:10.20M

PE:-0.10

High:0.1724

Open:0.1718

Low:0.1570

Close:0.1704

52wk High:3.05

52wk Low:0.1512

Shares:63.18M

Float Shares:56.90M

Volume Ratio:0.64

T/O Rate:31.92%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.6597

EPS(LYR):-2.7356

ROE:-7446.11%

ROA:-110.67%

PB:-5.78

PE(LYR):-0.06

Loading ...

Overview Company News Filings

Medicus Pharma submits clinical study design to FDA for Teverelix

EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate Patients

Benzinga_recent_news

Medicus clarifies SkinJect Phase 2 results, says 200µg dose leads registrational plan

Medicus Pharma Ltd - Development Focus Is on Active Treatment Arms in Phase 2 Study

THOMSON REUTERS

Medicus Pharma: Phase 2 Study Is "Proof of Concept" Exploratory Study, Primarily Focused on Achieving Meaningful Clinical (Visual) Clearance

THOMSON REUTERS

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Analysts Offer Insights on Healthcare Companies: Medicus Pharma Ltd (MDCX) and Butterfly Network (BFLY)

Medicus Pharma’s SkinJect Data Earns KOL Validation With 80% Response in Phase 2

Medicus Pharma reports principal investigator validation of Phase 2 data

BRIEF-Medicus Pharma Reports Kol Validation Of Skinject Phase 2 Data Of 80% Overall Response Rate

Medicus reports KOL validates SkinJect Phase 2 data showing 80% response rate

Medicus Pharma Highlights Strong SkinJect Phase 2 Results and AI-Driven Development Plan

Medicus Pharma reports 80% ORR in Phase 2 SkinJect 200µg cohort at Day 57; FY2025 cash and cash equivalents fall to $9 million at year-end

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Medicus Pharma Advances SkinJect and Teverelix Pipelines, Adds AI to Clinical Strategy

Medicus Pharma Ltd reports results for the quarter ended December 31 - Earnings Summary

Medicus Pharma FY2025 announces SkinJect SKNJCT-003 topline results; net loss climbs to $35.4 million

Medicus Pharma Q4 EPS $(0.83) Misses $(0.15) Estimate

Benzinga Earnings

Medicus Pharma FY2025 net loss more than doubled to $35.4 million; operating loss tripled to $34.4 million

Medicus Pharma Ltd expected to post a loss of 15 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/MDCX/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":0.1614,"timestamp":1789070400000,"preClose":0.1704,"halted":0,"volume":18164197,"hourTrading":{"tag":"盘前","latestPrice":0.1594,"preClose":0.1614,"latestTime":"07:21 EDT","volume":166568,"amount":26646.71246864,"timestamp":1789125669149,"change":-0.002,"changeRate":-0.012392,"amplitude":0.050186},"delay":0,"changeRate":-0.05281690140845075,"floatShares":56901000,"shares":63180610,"eps":-1.659689,"marketStatus":"Pre-Mkt","change":-0.009,"latestTime":"09-11 07:21:56 EDT","open":0.1718,"high":0.1724,"low":0.157,"amount":3142930.2997254203,"amplitude":0.090376,"askPrice":0.1635,"askSize":600,"bidPrice":0.1569,"bidSize":8,"shortable":3,"etf":0,"ttmEps":-1.659689,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789133400000},"marketStatusCode":1,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":0.1614,"preHourTrading":{"tag":"盘前","latestPrice":0.1594,"preClose":0.1614,"latestTime":"07:21 EDT","volume":166568,"amount":26646.71246864,"timestamp":1789125669149,"change":-0.002,"changeRate":-0.012392,"amplitude":0.050186},"postHourTrading":{"tag":"盘后","latestPrice":0.159501,"preClose":0.1614,"latestTime":"19:59 EDT","volume":887286,"amount":142298.89452,"timestamp":1789084777801,"change":-0.001899,"changeRate":-0.011766,"amplitude":0.043371},"volumeRatio":0.6431521156573451},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":56901000,"roa":"-110.67%","roe":"-7446.11%","lyrEps":-2.735593,"volumeRatio":0.6431521156573451,"shares":63180610,"dividePrice":0,"high":0.1724,"amplitude":0.090376,"preClose":0.1704,"low":0.157,"week52Low":0.1512,"pbRate":"-5.78","week52High":3.05,"institutionHeld":0,"latestPrice":0.1614,"committee":-0.973684,"eps":-1.659689,"divideRate":0,"volume":18164197,"delay":0,"ttmEps":-1.659689,"open":0.1718,"prevYearClose":1.53,"prevWeekClose":0.172,"prevMonthClose":0.2618,"prevQuarterClose":0.4463,"fiveDayClose":0.2599,"twentyDayClose":0.3311,"sixtyDayClose":0.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"MDCX","fiscalQuarterEnding":"2026/06","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2026-05-14","symbol":"MDCX","fiscalQuarterEnding":"2026/03","expectedEps":-0.18,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.31},{"market":"US","date":"2026-03-25","symbol":"MDCX","fiscalQuarterEnding":"2025/12","expectedEps":-0.32,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"post","actualEps":-0.82},{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"Post-Mkt","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1785297600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2026-09-10","current":-0.097247,"percent":0.996169,"low":-3.23298,"twenty":-2.159574,"median":-0.722924,"eighty":-0.335654,"high":-0.189555,"avg":-1.080014,"sd":0.94858,"marketCap":10765975},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830},{"date":"2025-12-19","current":-1.022869,"twenty":-2.897708,"median":-2.63428,"eighty":-1.31987,"marketCap":36568379},{"date":"2025-12-26","current":-0.955088,"twenty":-2.897553,"median":-2.584818,"eighty":-1.266827,"marketCap":34145173},{"date":"2026-01-02","current":-1.074791,"twenty":-2.896932,"median":-2.511859,"eighty":-1.220048,"marketCap":38424640},{"date":"2026-01-09","current":-1.095865,"twenty":-2.885734,"median":-2.329463,"eighty":-1.179996,"marketCap":39178064},{"date":"2026-01-16","current":-0.976444,"twenty":-2.885734,"median":-2.178335,"eighty":-1.123965,"marketCap":34908660},{"date":"2026-01-23","current":-0.94132,"twenty":-2.866576,"median":-2.167912,"eighty":-1.101485,"marketCap":33652952},{"date":"2026-01-30","current":-0.878097,"twenty":-2.861786,"median":-2.115799,"eighty":-1.061072,"marketCap":31392680},{"date":"2026-02-06","current":-0.765701,"twenty":-2.861786,"median":-2.074108,"eighty":-1.022014,"marketCap":27374416},{"date":"2026-02-13","current":-0.709738,"twenty":-2.853549,"median":-1.933403,"eighty":-0.974021,"marketCap":25373688},{"date":"2026-02-20","current":-0.786136,"twenty":-2.850483,"median":-1.381324,"eighty":-0.961937,"marketCap":28104981},{"date":"2026-02-27","current":-0.97195,"twenty":-2.849812,"median":-1.344224,"eighty":-0.949581,"marketCap":34747976},{"date":"2026-03-06","current":-0.484474,"twenty":-2.849812,"median":-1.300152,"eighty":-0.949581,"marketCap":17320333},{"date":"2026-03-13","current":-0.412761,"twenty":-2.835443,"median":-1.263181,"eighty":-0.891018,"marketCap":14756541},{"date":"2026-03-20","current":-0.412761,"twenty":-2.825864,"median":-1.220048,"eighty":-0.847322,"marketCap":14756541},{"date":"2026-03-27","current":-0.387698,"twenty":-2.82079,"median":-1.201563,"eighty":-0.836077,"marketCap":18330934},{"date":"2026-04-02","current":-0.349652,"twenty":-2.811211,"median":-1.179996,"eighty":-0.820403,"marketCap":16532085},{"date":"2026-04-10","current":-0.367967,"twenty":-2.792337,"median":-1.125793,"eighty":-0.786136,"marketCap":17398052},{"date":"2026-04-17","current":-0.250001,"twenty":-2.775573,"median":-1.109135,"eighty":-0.744685,"marketCap":11820441},{"date":"2026-04-24","current":-0.276475,"twenty":-2.764797,"median":-1.099378,"eighty":-0.508201,"marketCap":13072156},{"date":"2026-05-01","current":-0.235266,"twenty":-2.75402,"median":-1.088841,"eighty":-0.417566,"marketCap":11123732},{"date":"2026-05-08","current":-0.277717,"twenty":-2.74923,"median":-1.069002,"eighty":-0.412761,"marketCap":13130880},{"date":"2026-05-15","current":-0.393186,"twenty":-2.733353,"median":-1.041354,"eighty":-0.401798,"marketCap":18590424},{"date":"2026-05-22","current":-0.308017,"twenty":-2.714637,"median":-1.024243,"eighty":-0.38811,"marketCap":15777036},{"date":"2026-05-29","current":-0.354651,"twenty":-2.703729,"median":-1.018593,"eighty":-0.376126,"marketCap":18165658},{"date":"2026-06-05","current":-0.402361,"twenty":-2.691755,"median":-0.976444,"eighty":-0.374724,"marketCap":20609444},{"date":"2026-06-12","current":-0.35842,"twenty":-2.672597,"median":-0.968141,"eighty":-0.372398,"marketCap":18358733},{"date":"2026-06-18","current":-0.378775,"twenty":-2.63428,"median":-0.962395,"eighty":-0.367967,"marketCap":19401342},{"date":"2026-06-26","current":-0.492235,"twenty":-2.63428,"median":-0.955088,"eighty":-0.371628,"marketCap":25212882},{"date":"2026-07-02","current":-0.442458,"twenty":-2.59471,"median":-0.94132,"eighty":-0.37203,"marketCap":22663265},{"date":"2026-07-10","current":-0.467347,"twenty":-2.543128,"median":-0.915037,"eighty":-0.3732,"marketCap":23938074},{"date":"2026-07-17","current":-0.449095,"twenty":-2.516028,"median":-0.871896,"eighty":-0.374395,"marketCap":23003214},{"date":"2026-07-24","current":-0.424981,"twenty":-2.511859,"median":-0.846653,"eighty":-0.374627,"marketCap":21768066},{"date":"2026-07-31","current":-0.290474,"twenty":-2.411802,"median":-0.843141,"eighty":-0.371929,"marketCap":14878433},{"date":"2026-08-07","current":-0.34025,"twenty":-2.326336,"median":-0.835949,"eighty":-0.363051,"marketCap":17428051},{"date":"2026-08-14","current":-0.353971,"twenty":-2.282561,"median":-0.821824,"eighty":-0.360424,"marketCap":20056990},{"date":"2026-08-21","current":-0.30351,"twenty":-2.211687,"median":-0.793282,"eighty":-0.354379,"marketCap":17197762},{"date":"2026-08-28","current":-0.298604,"twenty":-2.178335,"median":-0.778989,"eighty":-0.346389,"marketCap":16919767},{"date":"2026-09-04","current":-0.190112,"twenty":-2.172081,"median":-0.757549,"eighty":-0.339549,"marketCap":10772294},{"date":"2026-09-10","current":-0.190001,"twenty":-2.159574,"median":-0.722924,"eighty":-0.335654,"marketCap":10765975}],"updateTime":1789119738398},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625676030","title":"Medicus Pharma submits clinical study design to FDA for Teverelix","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676030","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676030?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:37","pubTimestamp":1775475431,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) announced the company has submitted an optimized Phase 2 clinical study design to the FDA for Teverelix, its investigational ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-clinical-study-design-to-fda-for-teverelix-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-clinical-study-design-to-fda-for-teverelix-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4139","BK4585","BK4588","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625766006","title":"EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2625766006","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625766006?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:16","pubTimestamp":1775474160,"startTime":"0","endTime":"0","summary":"Medicus Pharma submits Phase 2 design for Teverelix, targeting faster data readouts and lower costs in benign prostatic hyperplasia","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/06/Doctors-Are-Counseling-Prostate-Cancer-P.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/06/Doctors-Are-Counseling-Prostate-Cancer-P.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/penny-stocks/26/04/51654101/exclusive-medicus-pharma-refines-trial-design-to-cut-costs-accelerate-development-for-enlarged-prostate-patients","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/penny-stocks/26/04/51654101/exclusive-medicus-pharma-refines-trial-design-to-cut-costs-accelerate-development-for-enlarged-prostate-patients","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","AAQC","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590049","title":"Medicus clarifies SkinJect Phase 2 results, says 200µg dose leads registrational plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590049?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:33","pubTimestamp":1775043200,"startTime":"0","endTime":"0","summary":"Medicus Pharma issued clarification on March 5 topline Phase 2 results for SkinJect  in nodular basal cell carcinoma, flagging confusion tied to device-only arm.Development focus shifted to active doxorubicin microneedle array cohorts, with 200g positioned as lead dose for registrational planning.Day 57 data for 200g showed 73% clinical clearance, 40% histological response.Clinical Study Report expected to center on 100g and 200g efficacy, treating device-only arm as supportive non-pivotal information.Registrational strategy targets 200g regimen ahead of planned FDA end-of-Phase 2 meeting, using 505 pathway.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL1vy6f0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590091","title":"Medicus Pharma Ltd - Development Focus Is on Active Treatment Arms in Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590091?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:30","pubTimestamp":1775043040,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0NX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590013","title":"Medicus Pharma: Phase 2 Study Is \"Proof of Concept\" Exploratory Study, Primarily Focused on Achieving Meaningful Clinical (Visual) Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590013?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:30","pubTimestamp":1775043040,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0NX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624305518","title":"Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset","url":"https://stock-news.laohu8.com/highlight/detail?id=2624305518","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624305518?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:30","pubTimestamp":1775043000,"startTime":"0","endTime":"0","summary":"Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancerPHILADELPHIA, April  01, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASD","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/01/3266511/0/en/Medicus-Pharma-Ltd-Clarifies-Positive-SkinJect-Phase-2-Dataset.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK4139","MDCX","BK4215","LU1169589451.USD","BK4023","BK4567","MNA","CSR","BCC","BK4104","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624531963","title":"Analysts Offer Insights on Healthcare Companies: Medicus Pharma Ltd (MDCX) and Butterfly Network (BFLY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624531963","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624531963?lang=en_us&edition=fundamental","pubTime":"2026-04-01 01:40","pubTimestamp":1774978807,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medicus Pharma Ltd (MDCX) and Butterfly Network (BFL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-medicus-pharma-ltd-mdcx-and-butterfly-network-bfly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-medicus-pharma-ltd-mdcx-and-butterfly-network-bfly-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","MDCX","XBI","LU0029874061.USD","BK4137","XLV","HCSG","BFLY","LU0128526141.USD","BK4585","BK4082","BK4581","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623344546","title":"Medicus Pharma’s SkinJect Data Earns KOL Validation With 80% Response in Phase 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2623344546","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623344546?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:16","pubTimestamp":1774883764,"startTime":"0","endTime":"0","summary":"The latest update is out from Medicus Pharma Ltd ( ($MDCX) ). Medicus Pharma reported that key opinion leader and principal investigator Dr. Babar ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharmas-skinject-data-earns-kol-validation-with-80-response-in-phase-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharmas-skinject-data-earns-kol-validation-with-80-response-in-phase-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KOL","BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345626","title":"Medicus Pharma reports principal investigator validation of Phase 2 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345626?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:38","pubTimestamp":1774877888,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) reported independent clinical validation of its Phase 2 SkinJect dataset from Dr. Babar Rao, principal investigator of the SK...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-reports-principal-investigator-validation-of-phase-2-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-reports-principal-investigator-validation-of-phase-2-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312255","title":"BRIEF-Medicus Pharma Reports Kol Validation Of Skinject Phase 2 Data Of 80% Overall Response Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312255","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312255?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:59","pubTimestamp":1774871997,"startTime":"0","endTime":"0","summary":"BRIEF-Medicus Pharma Reports Kol Validation Of Skinject Phase 2 Data Of 80% Overall Response RateMarch 30 (Reuters) - Medicus Pharma Ltd MDCX.O:MEDICUS PHARMA REPORTS KOL VALIDATION OF SKINJECT PHASE ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA6LQKPX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314170","title":"Medicus reports KOL validates SkinJect Phase 2 data showing 80% response rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314170","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314170?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:31","pubTimestamp":1774870300,"startTime":"0","endTime":"0","summary":"Medicus reported key opinion leader validation of Phase 2 SKNJCT-003 data for SkinJect in nodular basal cell carcinoma, supporting continued development and regulatory engagement.Results were already presented from randomized, double-blind, three-arm trial comparing microneedle-delivered doxorubicin versus device-only control.Lead 200 g cohort at Day 57 showed about 80% overall response rate, including 73% clinical clearance.Histological clearance in 200 g cohort reached 40%, supporting selection of 200 g as lead regimen for further trials.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL3kJhJp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","BK4112","MDCX","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","IE00BN0W2W23.USD","LU0314104364.USD","BK4588","SG9999014013.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622863027","title":"Medicus Pharma Highlights Strong SkinJect Phase 2 Results and AI-Driven Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2622863027","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622863027?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:20","pubTimestamp":1774531228,"startTime":"0","endTime":"0","summary":"An update from Medicus Pharma Ltd ( ($MDCX) ) is now available. Medicus Pharma plans a business update call to discuss new Phase 2 results for its ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-highlights-strong-skinject-phase-2-results-and-ai-driven-development-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-highlights-strong-skinject-phase-2-results-and-ai-driven-development-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CHAT","BK4139","AIPO","AGIX","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622854234","title":"Medicus Pharma reports 80% ORR in Phase 2 SkinJect 200µg cohort at Day 57; FY2025 cash and cash equivalents fall to $9 million at year-end","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854234?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:32","pubTimestamp":1774524729,"startTime":"0","endTime":"0","summary":"Medicus Pharma reports 80% ORR in Phase 2 SkinJect 200g cohort at Day 57; FY2025 cash and cash equivalents fall to $9 million at year-end. Medicus announced a business update conference call scheduled for 11:30 a.m. ET where it will present new analysis from its Phase 2 SkinJect study.The company said the 200 g cohort showed an overall response rate of 80% at Day 57 and included 15 patients.It also reported 73% clinical clearance and 40% histological complete response at Day 57 in the 200 g cohort.Medicus said it plans to develop an agentic AI-enabled clinical development platform focused on trial design and enrollment forecasting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLbWtmsV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014005.SGD","BK4112","IE00BN0W2V16.EUR","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","BK4588","MDCX","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852318","title":"Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852318","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852318?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:30","pubTimestamp":1774524600,"startTime":"0","endTime":"0","summary":"200g Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin CancerPHILADELPHIA, March  26, 2026 (GLOBE NEWSWI","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3262893/0/en/Medicus-Pharma-Business-Update-Call-to-Highlight-80-Overall-Response-Rate-ORR-in-Phase-2-SkinJect-Study-and-Agentic-AI-enabled-Drug-Development-Plan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","AGIX","BCC","BK4161","LU1169590202.USD","CR","AIPO","BK4213","CHAT","LU1169589451.USD","PD","BK4567","MNA","PR","BK4023","CSR","BK4139","ORR","MDCX","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622889786","title":"Medicus Pharma Advances SkinJect and Teverelix Pipelines, Adds AI to Clinical Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622889786","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622889786?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:13","pubTimestamp":1774487596,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd ( ($MDCX) ) has issued an announcement. Medicus Pharma reported audited full-year 2025 results and detailed substantial clinical...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-advances-skinject-and-teverelix-pipelines-adds-ai-to-clinical-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-advances-skinject-and-teverelix-pipelines-adds-ai-to-clinical-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCX","CHAT","AGIX","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622888383","title":"Medicus Pharma Ltd reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622888383","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622888383?lang=en_us&edition=fundamental","pubTime":"2026-03-26 07:07","pubTimestamp":1774480063,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd reports results for the quarter ended December 31 - Earnings SummaryMedicus Pharma Ltd MDCX.OQ reported a quarterly adjusted loss of 65 cents per share for the quarter ended Decembe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL8N40D2PP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622900204","title":"Medicus Pharma FY2025 announces SkinJect SKNJCT-003 topline results; net loss climbs to $35.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622900204","media":"Reuters","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622900204?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:50","pubTimestamp":1774471853,"startTime":"0","endTime":"0","summary":"Medicus reported topline results from its SKNJCT-003 Phase 2 study of its SkinJect program, positioning the asset for potential use in non-invasive treatment of nodular basal cell carcinoma.The company said the 200g cohort achieved 73% clinical clearance and 40% histological clearance at Day 57, which could support differentiation versus surgical standard-of-care pathways.Medicus expects completion of the clinical study report in Q2 2026, a step that could enable regulatory planning for the next development stage and potential partnering discussions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL2kdnzL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622002236","title":"Medicus Pharma Q4 EPS $(0.83) Misses $(0.15) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622002236","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622002236?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:40","pubTimestamp":1774471240,"startTime":"0","endTime":"0","summary":"Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.15) by 442.48 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51470321/medicus-pharma-q4-eps-0-83-misses-0-15-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Medicus Pharma Q4 EPS $(0.83) Misses $(0.15) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004974","title":"Medicus Pharma FY2025 net loss more than doubled to $35.4 million; operating loss tripled to $34.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004974","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004974?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:09","pubTimestamp":1774469374,"startTime":"0","endTime":"0","summary":"Medicus published its annual report  for the fiscal year ended Dec. 31, 2025, reporting a net loss of USD 35.4 million, or USD 2.74 per share.Total operating expenses rose more than tripled to USD 34.4 million, including general and administrative expense of USD 17.9 million and research and development expense of USD 7.7 million.General and administrative expense more than doubled, driven primarily by higher salaries and wages from increased headcount at board and management levels, as well as higher fees and added costs tied to being a public company, multiple financings and the Antev acquisition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDG","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4tfG4N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621516187","title":"Medicus Pharma Ltd  expected to post a loss of 15 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621516187","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621516187?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:14","pubTimestamp":1774037646,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd  expected to post a loss of15cents a share - Earnings Preview Medicus Pharma Ltd MDCX.OQ MDCX.O is expected to  show no change in quarterly revenue when it reports  results on March","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N40829U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":105,"code":"91000000","status":"200"}]}}